Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-κB signaling

Oral Oncology

Volumn 50, Issue 10, 2014, Pages 930-941

  Vander Broek, Robert ^a,b   Snow, Grace E ^a,b   Chen, Zhong ^a   Van Waes, Carter ^a  

^a NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Chemoprevention; Curcumin Cyclooxygenase (COX) inhibitors; Epidermal growth factor receptor (EGFR); Green tea extract (GTE); Head and neck cancer; Mammalian target of rapamycin (mTOR); Nuclear factor kappa B (NF B); Phosphatidylinositol 3 kinase (PI3K); Retinoids

Indexed keywords

ALPHA TOCOPHEROL; ANTIDIABETIC AGENT; CIGARETTE SMOKE; CURCUMIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GENISTEIN; GREEN TEA EXTRACT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR; RESVERATROL; RETINOID; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CARCINOGENESIS; CHEMOPROPHYLAXIS; EPSTEIN BARR VIRUS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LONG TERM EXPOSURE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); SIGNAL TRANSDUCTION; TRANSACTIVATION; VITAMIN SUPPLEMENTATION; WART VIRUS; CARCINOMA, SQUAMOUS CELL; DISEASE COURSE; HEAD AND NECK NEOPLASMS; METABOLISM;

ANTICARCINOGENIC AGENTS; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; HEAD AND NECK NEOPLASMS; HUMANS; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 84907865261     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2013.10.005     Document Type: Article

References (208)

1. M.B. Sporn, N.M. Dunlop, and D.L. Newton Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids) Fed Proc 35 1976 1332 1338
2. C.S. Scanlon, E.A. Van Tubergen, and R.C. Inglehart Biomarkers of Epithelial-Mesenchymal Transition in Squamous Cell Carcinoma J Dent Res 2012
3. S. Silverman Jr., M. Gorsky, and F. Lozada Oral leukoplakia and malignant transformation. A follow-up study of 257 patients Cancer 53 1984 563 568
4. D.P. Slaughter, H.W. Southwick, and W. Smejkal Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin Cancer 6 1953 963 968
5. J. Califano, P. van der Riet, and W. Westra Genetic progression model for head and neck cancer: implications for field cancerization Cancer Res 56 1996 2488 2492
6. C.M. Klass, and D.M. Shin Current status and future perspectives of chemoprevention in head and neck cancer Curr Cancer Drug Targets 7 2007 623 632
7. C. Dash, F.L. Chung, and J.A. Rohan A six-month crossover chemoprevention clinical trial of tea in smokers and non-smokers: methodological issues in a feasibility study BMC Complement Altern Med 12 2012 96
8. S. Luqman, and J.M. Pezzuto NFkappaB: a promising target for natural products in cancer chemoprevention Phytother Res 24 2010 949 963
9. M. Karin, and F.R. Greten NF-kappaB: linking inflammation and immunity to cancer development and progression Nat Rev Immunol 5 2005 749 759
10. J.A. DiDonato, F. Mercurio, and M. Karin NF-kappaB and the link between inflammation and cancer Immunol Rev 246 2012 379 400
11. C. Van Waes Nuclear factor-kappaB in development, prevention, and therapy of cancer Clin Cancer Res 13 2007 1076 1082
12. R. Sen, and D. Baltimore Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism Cell 47 1986 921 928
13. J.C. Betts, and G.J. Nabel Differential regulation of NF-kappaB2(p100) processing and control by amino-terminal sequences Mol Cell Biol 16 1996 6363 6371
14. C.M. Fan, and T. Maniatis Generation of p50 subunit of NF-kappa B by processing of p105 through an ATP-dependent pathway Nature 354 1991 395 398
15. M.S. Hayden, and S. Ghosh NF-kappaB, the first quarter-century: remarkable progress and outstanding questions Genes Dev 26 2012 203 234
16. S. Bergqvist, C.H. Croy, and M. Kjaergaard Thermodynamics reveal that helix four in the NLS of NF-kappaB p65 anchors IkappaBalpha, forming a very stable complex J Mol Biol 360 2006 421 434
17. P.A. Baeuerle IkappaB-NF-kappaB structures: at the interface of inflammation control Cell 95 1998 729 731
18. J.L. Luo, H. Kamata, and M. Karin IKK/NF-kappaB signaling: balancing life and death - a new approach to cancer therapy J Clin Invest 115 2005 2625 2632
19. Z.W. Li, W. Chu, and Y. Hu The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis J Exp Med 189 1999 1839 1845
20. E. Derudder, E. Dejardin, and L.L. Pritchard RelB/p50 dimers are differentially regulated by tumor necrosis factor-alpha and lymphotoxin-beta receptor activation: critical roles for p100 J Biol Chem 278 2003 23278 23284
21. S.C. Sun Non-canonical NF-kappaB signaling pathway Cell Res 21 2011 71 85
22. G. Xiao, E.W. Harhaj, and S.C. Sun NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100 Mol Cell 7 2001 401 409
23. H.L. Pahl Activators and target genes of Rel/NF-kappaB transcription factors Oncogene 18 1999 6853 6866
24. M.S. Hayden, and S. Ghosh Signaling to NF-kappaB Genes Dev 18 2004 2195 2224
25. P. Capaccio, G. Pruneri, and N. Carboni Cyclin D1 expression is predictive of occult metastases in head and neck cancer patients with clinically negative cervical lymph nodes Head Neck 22 2000 234 240
26. A. Namazie, S. Alavi, and O.I. Olopade Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors Laryngoscope 112 2002 472 481
27. J. Bartkova, J. Lukas, and H. Muller Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer Cancer Res 55 1995 949 956
28. C.Y. Wang, M.W. Mayo, and R.G. Korneluk NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation Science 281 1998 1680 1683
29. W.X. Zong, L.C. Edelstein, and C. Chen The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis Genes Dev 13 1999 382 387
30. G. Liao, M. Zhang, and E.W. Harhaj Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation J Biol Chem 279 2004 26243 26250
31. K. Tada, T. Okazaki, and S. Sakon Critical roles of TRAF2 and TRAF5 in tumor necrosis factor-induced NF-kappa B activation and protection from cell death J Biol Chem 276 2001 36530 36534
32. E. Meylan, and J. Tschopp The RIP kinases: crucial integrators of cellular stress Trends Biochem Sci 30 2005 151 159
33. A. Oeckinghaus, M.S. Hayden, and S. Ghosh Crosstalk in NF-kappaB signaling pathways Nat Immunol 12 2011 695 708
34. O.N. Ozes, L.D. Mayo, and J.A. Gustin NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase Nature 401 1999 82 85
35. D.M. Parkin, F. Bray, and J. Ferlay Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108
36. A. Jemal, R. Siegel, and J. Xu Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
37. A. Churg, J. Dai, and H. Tai Tumor necrosis factor-alpha is central to acute cigarette smoke-induced inflammation and connective tissue breakdown Am J Respir Crit Care Med 166 2002 849 854
38. K.F. Chung Inflammatory mediators in chronic obstructive pulmonary disease Curr Drug Targets Inflamm Allergy 4 2005 619 625
39. J.S. Wolf, Z. Chen, and G. Dong IL (interleukin)-1alpha promotes nuclear factor-kappaB and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas Clin Cancer Res 7 2001 1812 1820
40. C.T. Allen, J.L. Ricker, and Z. Chen Role of activated nuclear factor-kappaB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck Head Neck 29 2007 959 971
41. C.H. Druzgal, Z. Chen, and N.T. Yeh A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma Head Neck 27 2005 771 784
42. G. Dong, Z. Chen, and T. Kato The host environment promotes the constitutive activation of nuclear factor-kappaB and proinflammatory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma Cancer Res 59 1999 3495 3504
43. R.J. Anto, A. Mukhopadhyay, and S. Shishodia Cigarette smoke condensate activates nuclear transcription factor-kappaB through phosphorylation and degradation of IkappaB(alpha): correlation with induction of cyclooxygenase-2 Carcinogenesis 23 2002 1511 1518
44. S.C. Lin, S.Y. Lu, and S.Y. Lee Areca (betel) nut extract activates mitogen-activated protein kinases and NF-kappaB in oral keratinocytes Int J Cancer 116 2005 526 535
45. C.C. Bancroft, Z. Chen, and J. Yeh Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines Int J Cancer 99 2002 538 548
46. M. Bond, R.P. Fabunmi, and A.H. Baker Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B FEBS Lett 435 1998 29 34
47. P. Oc Rhys-Evans PH, Eccles SA: Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck Arch Otolaryngol Head Neck Surg 127 2001 813 820
48. F. Riedel, K. Gotte, and J. Schwalb Expression of 92-kDa type IV collagenase correlates with angiogenic markers and poor survival in head and neck squamous cell carcinoma Int J Oncol 17 2000 1099 1105
49. Y.K. Mburu, A.M. Egloff, and W.H. Walker Chemokine receptor 7 (CCR7) gene expression is regulated by NF-kappaB and activator protein 1 (AP1) in metastatic squamous cell carcinoma of head and neck (SCCHN) J Biol Chem 287 2012 3581 3590
50. J. Wang, R.R. Seethala, and Q. Zhang Autocrine and paracrine chemokine receptor 7 activation in head and neck cancer: implications for therapy J Natl Cancer Inst 100 2008 502 512
51. A.K. Chaturvedi, E.A. Engels, and R.M. Pfeiffer Human papillomavirus and rising oropharyngeal cancer incidence in the United States J Clin Oncol 29 2011 4294 4301
52. M.A. O'Rorke, M.V. Ellison, and L.J. Murray Human papillomavirus related head and neck cancer survival: a systematic review and meta-analysis Oral Oncol 48 2012 1191 1201
53. M. Rolfe, P. Beer-Romero, and S. Glass Reconstitution of p53-ubiquitinylation reactions from purified components: the role of human ubiquitin-conjugating enzyme UBC4 and E6-associated protein (E6AP) Proc Natl Acad Sci USA 92 1995 3264 3268
54. N. Dyson, P.M. Howley, and K. Munger The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product Science 243 1989 934 937
55. M.A. James, J.H. Lee, and A.J. Klingelhutz Human papillomavirus type 16 E6 activates NF-kappaB, induces cIAP-2 expression, and protects against apoptosis in a PDZ binding motif-dependent manner J Virol 80 2006 5301 5307
56. M. Branca, C. Giorgi, and M. Ciotti Upregulation of nuclear factor-kappaB (NF-kappaB) is related to the grade of cervical intraepithelial neoplasia, but is not an independent predictor of high-risk human papillomavirus or disease outcome in cervical cancer Diagn Cytopathol 34 2006 555 563
57. A. Nair, M. Venkatraman, and T.T. Maliekal NF-kappaB is constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix Oncogene 22 2003 50 58
58. M.A. Vasef, A. Ferlito, and L.M. Weiss Nasopharyngeal carcinoma, with emphasis on its relationship to Epstein-Barr virus Ann Otol Rhinol Laryngol 106 1997 348 356
59. W. Shi, C. Bastianutto, and A. Li Multiple dysregulated pathways in nasopharyngeal carcinoma revealed by gene expression profiling Int J Cancer 119 2006 2467 2475
60. Y. Zhang, J.Y. Lang, and L. Liu Association of nuclear factor kappaB expression with a poor outcome in nasopharyngeal carcinoma Med Oncol 28 2011 1338 1342
61. B.A. Mainou, and N. Raab-Traub LMP1 strain variants: biological and molecular properties J Virol 80 2006 6458 6468
62. J. Chou, Y.C. Lin, and J. Kim Nasopharyngeal carcinoma - review of the molecular mechanisms of tumorigenesis Head Neck 30 2008 946 963
63. P.G. Atkinson, H.J. Coope, and M. Rowe Latent membrane protein 1 of Epstein-Barr virus stimulates processing of NF-kappa B2 p100 to p52 J Biol Chem 278 2003 51134 51142
64. V. Soni, E. Cahir-McFarland, and E. Kieff LMP1 TRAFficking activates growth and survival pathways Adv Exp Med Biol 597 2007 173 187
65. S.C. Gupta, C. Sundaram, and S. Reuter Inhibiting NF-kappaB activation by small molecules as a therapeutic strategy Biochim Biophys Acta 1799 2010 775 787
66. M. Karin, Y. Yamamoto, and Q.M. Wang The IKK NF-kappa B system: a treasure trove for drug development Nat Rev Drug Discov 3 2004 17 26
67. H.J. Kim, N. Hawke, and A.S. Baldwin NF-kappaB and IKK as therapeutic targets in cancer Cell Death Differ 13 2006 738 747
68. V. Tergaonkar NFkappaB pathway: a good signaling paradigm and therapeutic target Int J Biochem Cell Biol 38 2006 1647 1653
69. C. Van Waes, A.A. Chang, and P.F. Lebowitz Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma Int J Radiat Oncol Biol Phys 63 2005 1400 1412
70. M.A. Rahman, A.R. Amin, and D.M. Shin Chemopreventive potential of natural compounds in head and neck cancer Nutr Cancer 62 2010 973 987
71. A.S. Holpuch, K.G. Desai, and S.P. Schwendeman Optimizing therapeutic efficacy of chemopreventive agents: a critical review of delivery strategies in oral cancer chemoprevention clinical trials J Carcinog 10 2011 23
72. N. Oridate, D. Lotan, and X.C. Xu Differential induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl)retinamide in human head and neck squamous cell carcinoma cell lines Clin Cancer Res 2 1996 855 863
73. A. Cras, B. Politis, and N. Balitrand Bexarotene via CBP/p300 induces suppression of NF-kappaB-dependent cell growth and invasion in thyroid cancer Clin Cancer Res 18 2012 442 453
74. F. Chiesa, N. Tradati, and R. Grigolato Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results Int J Cancer 115 2005 625 629
75. H.S. Garewal, R.V. Katz, and F. Meyskens Beta-carotene produces sustained remissions in patients with oral leukoplakia: results of a multicenter prospective trial Arch Otolaryngol Head Neck Surg 125 1999 1305 1310
76. W.K. Hong, J. Endicott, and L.M. Itri 13-cis-retinoic acid in the treatment of oral leukoplakia N Engl J Med 315 1986 1501 1505
77. S.M. Lippman, J.J. Lee, and J.W. Martin Fenretinide activity in retinoid-resistant oral leukoplakia Clin Cancer Res 12 2006 3109 3114
78. W.N. William Jr., J.J. Lee, and S.M. Lippman High-dose fenretinide in oral leukoplakia Cancer Prev Res (Phila) 2 2009 22 26
79. S. Shishodia, A.M. Gutierrez, and R. Lotan N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products Cancer Res 65 2005 9555 9565
80. C. Guruvayoorappan, and G. Kuttan 13 cis-retinoic acid regulates cytokine production and inhibits angiogenesis by disrupting endothelial cell migration and tube formation J Exp Ther Oncol 7 2008 173 182
81. H.E. Kleiner-Hancock, R. Shi, and A. Remeika Effects of ATRA combined with citrus and ginger-derived compounds in human SCC xenografts BMC Cancer 10 2010 394
82. G.M. Gaeta, F. Gombos, and F. Femiano Acitretin and treatment of the oral leucoplakias. A model to have an active molecules release J Eur Acad Dermatol Venereol 14 2000 473 478
83. S.T. Mayne, B. Cartmel, and M. Baum Randomized trial of supplemental beta-carotene to prevent second head and neck cancer Cancer Res 61 2001 1457 1463
84. V.A. Papadimitrakopoulou, J.J. Lee, and W.N. William Jr. Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy J Clin Oncol 27 2009 599 604
85. C.F. Perry, M. Stevens, and I. Rabie Chemoprevention of head and neck cancer with retinoids: a negative result Arch Otolaryngol Head Neck Surg 131 2005 198 203
86. S. Toma, L. Bonelli, and A. Sartoris 13-cis retinoic acid in head and neck cancer chemoprevention: results of a randomized trial from the Italian Head and Neck Chemoprevention Study Group Oncol Rep 11 2004 1297 1305
87. S. Toma, L. Bonelli, and A. Sartoris Beta-carotene supplementation in patients radically treated for stage I-II head and neck cancer: results of a randomized trial Oncol Rep 10 2003 1895 1901
88. N. van Zandwijk, O. Dalesio, and U. Pastorino EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups J Natl Cancer Inst 92 2000 977 986
89. M.A. Hildebrandt, S.M. Lippman, and C.J. Etzel Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention Clin Cancer Res 18 2012 3705 3713
90. J.R. Grandis, and D.J. Tweardy Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer Cancer Res 53 1993 3579 3584
91. J.R. Grandis, A. Chakraborty, and Q. Zeng Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells J Cell Biochem 69 1998 55 62
92. S. Wheeler, D.R. Siwak, and R. Chai Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma Clin Cancer Res 18 2012 2278 2289
93. C.H. Squarize, R.M. Castilho, and V. Sriuranpong Molecular cross-talk between the NFkappaB and STAT3 signaling pathways in head and neck squamous cell carcinoma Neoplasia 8 2006 733 746
94. F.G. Pernas, C.T. Allen, and M.E. Winters Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer Clin Cancer Res 15 2009 2361 2372
95. C. Van Waes, C.T. Allen, and D. Citrin Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer Int J Radiat Oncol Biol Phys 77 2010 447 454
96. A.R. Amin, O. Kucuk, and F.R. Khuri Perspectives for cancer prevention with natural compounds J Clin Oncol 27 2009 2712 2725
97. Y.C. Chang, P.N. Chen, and S.C. Chu Black Tea Polyphenols Reverse Epithelial-to-Mesenchymal Transition and Suppress Cancer Invasion and Proteases in Human Oral Cancer Cells J Agric Food Chem 2012
98. C.F. de Moura, J. Noguti, and G.P. de Jesus Polyphenols as a chemopreventive agent in oral carcinogenesis: putative mechanisms of action using in-vitro and in-vivo test systems Eur J Cancer Prev 2012
99. C.S. Yang, H. Wang, and G.X. Li Cancer prevention by tea: evidence from laboratory studies Pharmacol Res 64 2011 113 122
100. F.R. Khuri, and D.M. Shin Head and neck cancer chemoprevention gets a shot in the arm J Clin Oncol 26 2008 345 347
101. C.S. Yang, X. Wang, and G. Lu Cancer prevention by tea: animal studies, molecular mechanisms and human relevance Nat Rev Cancer 9 2009 429 439
102. M. Masuda, M. Suzui, and J.T. Lim Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction J Exp Ther Oncol 2 2002 350 359
103. D.M. Shin Oral cancer prevention advances with a translational trial of green tea Cancer Prev Res (Phila) 2 2009 919 921
104. M. Suganuma, E. Sueoka, and N. Sueoka Mechanisms of cancer prevention by tea polyphenols based on inhibition of TNF-alpha expression Biofactors 13 2000 67 72
105. C.S. Yang, P. Maliakal, and X. Meng Inhibition of carcinogenesis by tea Annu Rev Pharmacol Toxicol 42 2002 25 54
106. Z. Yan, T. Yong-Guang, and L. Fei-Jun Interference effect of epigallocatechin-3-gallate on targets of nuclear factor kappaB signal transduction pathways activated by EB virus encoded latent membrane protein 1 Int J Biochem Cell Biol 36 2004 1473 1481
107. A.R. Amin, F.R. Khuri, and Z.G. Chen Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and epigallocatechin-3-gallate: the role of p53-dependent inhibition of nuclear factor-kappaB Cancer Prev Res (Phila) 2 2009 538 545
108. A.S. Tsao, D. Liu, and J. Martin Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions Cancer Prev Res (Phila) 2 2009 931 941
109. V.M. Duarte, E. Han, and M.S. Veena Curcumin enhances the effect of cisplatin in suppression of head and neck squamous cell carcinoma via inhibition of IKKbeta protein of the NFkappaB pathway Mol Cancer Ther 9 2010 2665 2675
110. S. Aggarwal, Y. Takada, and S. Singh Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling Int J Cancer 111 2004 679 692
111. M.M. LoTempio, M.S. Veena, and H.L. Steele Curcumin suppresses growth of head and neck squamous cell carcinoma Clin Cancer Res 11 2005 6994 7002
112. Y.T. Lin, L.F. Wang, and Y.C. Hsu Curcuminoids suppress the growth of pharynx and nasopharyngeal carcinoma cells through induced apoptosis J Agric Food Chem 57 2009 3765 3770
113. C. Meyer, R. Pries, and B. Wollenberg Established and novel NF-kappaB inhibitors lead to downregulation of TLR3 and the proliferation and cytokine secretion in HNSCC Oral Oncol 47 2011 818 826
114. C. Sharma, J. Kaur, and S. Shishodia Curcumin down regulates smokeless tobacco-induced NF-kappaB activation and COX-2 expression in human oral premalignant and cancer cells Toxicology 228 2006 1 15
115. S. Liao, J. Xia, and Z. Chen Inhibitory effect of curcumin on oral carcinoma CAL-27 cells via suppression of Notch-1 and NF-kappaB signaling pathways J Cell Biochem 112 2011 1055 1065
116. H.K. Shin, J. Kim, and E.J. Lee Inhibitory effect of curcumin on motility of human oral squamous carcinoma YD-10B cells via suppression of ERK and NF-kappaB activations Phytother Res 24 2010 577 582
117. T.S. Wong, W.S. Chan, and C.H. Li Curcumin alters the migratory phenotype of nasopharyngeal carcinoma cells through up-regulation of E-cadherin Anticancer Res 30 2010 2851 2856
118. C.A. Clark, M.D. McEachern, and S.H. Shah Curcumin inhibits carcinogen and nicotine-induced Mammalian target of rapamycin pathway activation in head and neck squamous cell carcinoma Cancer Prev Res (Phila) 3 2010 1586 1595
119. D. Wang, M.S. Veena, and K. Stevenson Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway Clin Cancer Res 14 2008 6228 6236
120. S. Zhu, T.W. Moore, and X. Lin Synthetic curcumin analog EF31 inhibits the growth of head and neck squamous cell carcinoma xenografts Integr Biol (Camb) 4 2012 633 640
121. S. Tuttle, L. Hertan, and N. Daurio The chemopreventive and clinically used agent curcumin sensitizes HPV (-) but not HPV (+) HNSCC to ionizing radiation, in vitro and in a mouse orthotopic model Cancer Biol Ther 13 2012 575 584
122. G. Chan, J.O. Boyle, and E.K. Yang Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck Cancer Res 59 1999 991 994
123. S.H. Hong, F.G. Ondrey, and I.M. Avis Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine IL-6: a general role for inflammation? FASEB J 14 2000 1499 1507
124. J.L. Mulshine, J.C. Atkinson, and R.O. Greer Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia Clin Cancer Res 10 2004 1565 1573
125. J. Renkonen, H. Wolff, and T. Paavonen Expression of cyclo-oxygenase-2 in human tongue carcinoma and its precursor lesions Virchows Arch 440 2002 594 597
126. Y.Y. Kim, E.J. Lee, and Y.K. Kim Anti-cancer effects of celecoxib in head and neck carcinoma Mol Cells 29 2010 185 194
127. L. Feng, and Z. Wang Chemopreventive effect of celecoxib in oral precancers and cancers Laryngoscope 116 2006 1842 1845
128. Y. Hao, T. Xie, and A. Korotcov Salvianolic acid B inhibits growth of head and neck squamous cell carcinoma in vitro and in vivo via cyclooxygenase-2 and apoptotic pathways Int J Cancer 124 2009 2200 2209
129. G. Nishimura, S. Yanoma, and H. Mizuno A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells Jpn J Cancer Res 90 1999 1152 1162
130. Z. Wang, C.F. Fuentes, and S.M. Shapshay Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell Laryngoscope 112 2002 839 843
131. W.R. Panje Regression of head and neck carcinoma with a prostaglandin-synthesis inhibitor Arch Otolaryngol 107 1981 658 663
132. F. Lerebours, S. Vacher, and C. Andrieu NF-kappa B genes have a major role in inflammatory breast cancer BMC Cancer 8 2008 41
133. W.S. Santhi, P. Sebastian, and B.T. Varghese NF-kappaB and COX-2 during oral tumorigenesis and in assessment of minimal residual disease in surgical margins Exp Mol Pathol 81 2006 123 130
134. M. Sawhney, N. Rohatgi, and J. Kaur Expression of NF-kappaB parallels COX-2 expression in oral precancer and cancer: association with smokeless tobacco Int J Cancer 120 2007 2545 2556
135. R.S. Bresalier, R.S. Sandler, and H. Quan Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N Engl J Med 352 2005 1092 1102
136. T. Kitamura, M. Itoh, and T. Noda Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice Int J Cancer 109 2004 576 580
137. S. Shishodia, and B.B. Aggarwal Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9 Cancer Res 64 2004 5004 5012
138. U. Raju, H. Ariga, and K. Dittmann Inhibition of DNA repair as a mechanism of enhanced radioresponse of head and neck carcinoma cells by a selective cyclooxygenase-2 inhibitor, celecoxib Int J Radiat Oncol Biol Phys 63 2005 520 528
139. R. Brigelius-Flohe, and M.G. Traber Vitamin E: function and metabolism FASEB J 13 1999 1145 1155
140. K. Husain, R.A. Francois, and T. Yamauchi Vitamin E delta-tocotrienol augments the antitumor activity of gemcitabine and suppresses constitutive NF-kappaB activation in pancreatic cancer Mol Cancer Ther 10 2011 2363 2372
141. K.A. Manu, M.K. Shanmugam, and L. Ramachandran First evidence that gamma-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-kappaB pathway Clin Cancer Res 18 2012 2220 2229
142. H. Yang, X. Jia, and X. Chen Time-selective chemoprevention of vitamin E and selenium on esophageal carcinogenesis in rats: the possible role of nuclear factor kappaB signaling pathway Int J Cancer 131 2012 1517 1527
143. X. Ji, Z. Wang, and A. Geamanu Inhibition of cell growth and induction of apoptosis in non-small cell lung cancer cells by delta-tocotrienol is associated with notch-1 down-regulation J Cell Biochem 112 2011 2773 2783
144. X.F. Wang, Y. Xie, and H.G. Wang Alpha-Tocopheryl succinate induces apoptosis in erbB2-expressing breast cancer cell via NF-kappaB pathway Acta Pharmacol Sin 31 2010 1604 1610
145. K. Kanai, E. Kikuchi, and S. Mikami Vitamin E succinate induced apoptosis and enhanced chemosensitivity to paclitaxel in human bladder cancer cells in vitro and in vivo Cancer Sci 101 2010 216 223
146. W.L. Xu, J.R. Liu, and H.K. Liu Inhibition of proliferation and induction of apoptosis by gamma-tocotrienol in human colon carcinoma HT-29 cells Nutrition 25 2009 555 566
147. P.L. Crispen, R.G. Uzzo, and K. Golovine Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemoprevention Prostate 67 2007 582 590
148. S.E. Benner, R.J. Winn, and S.M. Lippman Regression of oral leukoplakia with alpha-tocopherol: a community clinical oncology program chemoprevention study J Natl Cancer Inst 85 1993 44 47
149. G.E. Kaugars, S. Silverman Jr., and J.G. Lovas A clinical trial of antioxidant supplements in the treatment of oral leukoplakia Oral Surg Oral Med Oral Pathol 78 1994 462 468
150. J.A. Seixas-Silva Jr., T. Richards, and F.R. Khuri Phase 2 bioadjuvant study of interferon alfa-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: long-term follow-up Arch Otolaryngol Head Neck Surg 131 2005 304 307
151. D.M. Shin, F.R. Khuri, and B. Murphy Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial J Clin Oncol 19 2001 3010 3017
152. D. Zaridze, T. Evstifeeva, and P. Boyle Chemoprevention of oral leukoplakia and chronic esophagitis in an area of high incidence of oral and esophageal cancer Ann Epidemiol 3 1993 225 234
153. I. Bairati, F. Meyer, and E. Jobin Antioxidant vitamins supplementation and mortality: a randomized trial in head and neck cancer patients Int J Cancer 119 2006 2221 2224
154. H.C. Dan, and A.S. Baldwin Differential involvement of IkappaB kinases alpha and beta in cytokine- and insulin-induced mammalian target of rapamycin activation determined by Akt J Immunol 180 2008 7582 7589
155. H.C. Dan, M.J. Cooper, and P.C. Cogswell Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK Genes Dev 22 2008 1490 1500
156. P. Amornphimoltham, V. Patel, and A. Sodhi Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck Cancer Res 65 2005 9953 9961
157. A.A. Molinolo, C. Marsh, and M. El Dinali MTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas Clin Cancer Res 18 2012 2558 2568
158. R. Czerninski, P. Amornphimoltham, and V. Patel Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model Cancer Prev Res (Phila) 2 2009 27 36
159. P. Amornphimoltham, K. Leelahavanichkul, and A. Molinolo Inhibition of Mammalian target of rapamycin by rapamycin causes the regression of carcinogen-induced skin tumor lesions Clin Cancer Res 14 2008 8094 8101
160. Z.J. Sun, L. Zhang, and B. Hall Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model Clin Cancer Res 18 2012 5304 5313
161. A.R. Raimondi, A. Molinolo, and J.S. Gutkind Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model Cancer Res 69 2009 4159 4166
162. Nathan C-AO AN, Sibley D, et al. In vivo and in vitro effect of CCI-779 a rapamycin analogue on HNSCC. AACR, Meeting Abstracts. C:850; 2004.
163. R. Govindarajan, L. Ratnasinghe, and D.L. Simmons Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes J Clin Oncol 25 2007 1476 1481
164. R.S.E. Govindarajan, D.L. Simmons, and N.P. NP. Thiazolidinedione (TZD) exposure and risk of squamous cell carcinoma of head and neck (SCCHN). 2007 ASCO Annual Meeting Proceedings Part I J Clin Oncol 25 2007 1511
165. R. Suzuki, H. Kohno, and M. Suzui An animal model for the rapid induction of tongue neoplasms in human c-Ha-ras proto-oncogene transgenic rats by 4-nitroquinoline 1-oxide: its potential use for preclinical chemoprevention studies Carcinogenesis 27 2006 619 630
166. K. Yoshida, Y. Hirose, and T. Tanaka Inhibitory effects of troglitazone, a peroxisome proliferator-activated receptor gamma ligand, in rat tongue carcinogenesis initiated with 4-nitroquinoline 1-oxide Cancer Sci 94 2003 365 371
167. V.G. Keshamouni, D.A. Arenberg, and R.C. Reddy PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer Neoplasia 7 2005 294 301
168. A. Papi, T. Guarnieri, and G. Storci Nuclear receptors agonists exert opposing effects on the inflammation dependent survival of breast cancer stem cells Cell Death Differ 19 2012 1208 1219
169. J.O. Ban, D.H. Kwak, and J.H. Oh Suppression of NF-kappaB and GSK-3beta is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone Chem Biol Interact 188 2010 75 85
170. J.O. Ban, J.H. Oh, and S.M. Son Troglitazone, a PPAR agonist, inhibits human prostate cancer cell growth through inactivation of NFkappaB via suppression of GSK-3beta expression Cancer Biol Ther 12 2011 288 296
171. F. Chen, and L.E. Harrison Ciglitazone induces early cellular proliferation and NF-kappaB transcriptional activity in colon cancer cells through p65 phosphorylation Int J Biochem Cell Biol 37 2005 645 654
172. C.Z. Wang, Y. Zhang, and X.D. Li PPARgamma agonist suppresses TLR4 expression and TNF-alpha production in LPS stimulated monocyte leukemia cells Cell Biochem Biophys 60 2011 167 172
173. H. Patel, R.H. Younis, and R.A. Ord Differential expression of organic cation transporter OCT-3 in oral premalignant and malignant lesions: potential implications in the antineoplastic effects of metformin J Oral Pathol Med 2012
174. L. Vitale-Cross, A.A. Molinolo, and D. Martin Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions Cancer Prev Res (Phila) 5 2012 562 573
175. N. Rhodus, M. Rohrer, and S. Pambuccian Phase IIa chemoprevention clinical trial of pioglitazone for oral leukoplakia J Dent Res 90 2011 945
176. G.K. Harris, A. Gupta, and R.G. Nines Effects of lyophilized black raspberries on azoxymethane-induced colon cancer and 8-hydroxy-2'-deoxyguanosine levels in the Fischer 344 rat Nutr Cancer 40 2001 125 133
177. L.A. Kresty, M.A. Morse, and C. Morgan Chemoprevention of esophageal tumorigenesis by dietary administration of lyophilized black raspberries Cancer Res 61 2001 6112 6119
178. C. Huang, Y. Huang, and J. Li Inhibition of benzo(a)pyrene diol-epoxide-induced transactivation of activated protein 1 and nuclear factor kappaB by black raspberry extracts Cancer Res 62 2002 6857 6863
179. G.D. Stoner, L.S. Wang, and N. Zikri Cancer prevention with freeze-dried berries and berry components Semin Cancer Biol 17 2007 403 410
180. B.S. Shumway, L.A. Kresty, and P.E. Larsen Effects of a topically applied bioadhesive berry gel on loss of heterozygosity indices in premalignant oral lesions Clin Cancer Res 14 2008 2421 2430
181. S.M. Gadgeel, S. Ali, and P.A. Philip Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines Cancer 115 2009 2165 2176
182. L. Gong, Y. Li, and A. Nedeljkovic-Kurepa Inactivation of NF-kappaB by genistein is mediated via Akt signaling pathway in breast cancer cells Oncogene 22 2003 4702 4709
183. Y. Li, and F.H. Sarkar Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway Clin Cancer Res 8 2002 2369 2377
184. Y. Ma, J. Wang, and L. Liu Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: role of Akt and nuclear factor-kappaB Cancer Lett 301 2011 75 84
185. H. Pan, W. Zhou, and W. He Genistein inhibits MDA-MB-231 triple-negative breast cancer cell growth by inhibiting NF-kappaB activity via the Notch-1 pathway Int J Mol Med 30 2012 337 343
186. Z. Wang, Y. Zhang, and S. Banerjee Inhibition of nuclear factor kappab activity by genistein is mediated via Notch-1 signaling pathway in pancreatic cancer cells Int J Cancer 118 2006 1930 1936
187. B. Zhang, Z.L. Shi, and B. Liu Enhanced anticancer effect of gemcitabine by genistein in osteosarcoma: the role of Akt and nuclear factor-kappaB Anticancer Drugs 21 2010 288 296
188. S. Ali, L. Varghese, and L. Pereira Sensitization of squamous cell carcinoma to cisplatin induced killing by natural agents Cancer Lett 278 2009 201 209
189. B.B. Aggarwal, A. Bhardwaj, and R.S. Aggarwal Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies Anticancer Res 24 2004 2783 2840
190. T.M. Elattar, and A.S. Virji The effect of red wine and its components on growth and proliferation of human oral squamous carcinoma cells Anticancer Res 19 1999 5407 5414
191. Y.J. Surh, Y.J. Hurh, and J.Y. Kang Resveratrol, an antioxidant present in red wine, induces apoptosis in human promyelocytic leukemia (HL-60) cells Cancer Lett 140 1999 1 10
192. Z. Estrov, S. Shishodia, and S. Faderl Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells Blood 102 2003 987 995
193. B.A. Narayanan, N.K. Narayanan, and G.G. Re Differential expression of genes induced by resveratrol in LNCaP cells: P53-mediated molecular targets Int J Cancer 104 2003 204 212
194. Y.A. Kim, W.H. Lee, and T.H. Choi Involvement of p21WAF1/CIP1, pRB, Bax and NF-kappaB in induction of growth arrest and apoptosis by resveratrol in human lung carcinoma A549 cells Int J Oncol 23 2003 1143 1149
195. J.H. Jang, and Y.J. Surh Protective effects of resveratrol on hydrogen peroxide-induced apoptosis in rat pheochromocytoma (PC12) cells Mutat Res 496 2001 181 190
196. K.R. Patel, E. Scott, and V.A. Brown Clinical trials of resveratrol Ann NY Acad Sci 1215 2011 161 169
197. S.R. Mallery, J.C. Zwick, and P. Pei Topical application of a bioadhesive black raspberry gel modulates gene expression and reduces cyclooxygenase 2 protein in human premalignant oral lesions Cancer Res 68 2008 4945 4957
198. K.G. Desai, S.R. Mallery, and A.S. Holpuch Development and in vitro-in vivo evaluation of fenretinide-loaded oral mucoadhesive patches for site-specific chemoprevention of oral cancer Pharm Res 28 2011 2599 2609
199. C.M. Rudin, E.E. Cohen, and V.A. Papadimitrakopoulou An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia J Clin Oncol 21 2003 4546 4552
200. Y. Li, L.J. Li, and S.T. Zhang In vitro and clinical studies of gene therapy with recombinant human adenovirus-p53 injection for oral leukoplakia Clin Cancer Res 15 2009 6724 6731
201. S. Zhang, Y. Li, and L. Li Phase I study of repeated intraepithelial delivery of adenoviral p53 in patients with dysplastic oral leukoplakia J Oral Maxillofac Surg 67 2009 1074 1082
202. V.A. Papadimitrakopoulou, W.N. William Jr., and A.J. Dannenberg Pilot randomized phase II study of celecoxib in oral premalignant lesions Clin Cancer Res 14 2008 2095 2101
203. L.J. Wirth, J.F. Krane, and Y. Li A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions Cancer Prev Res (Phila) 1 2008 339 348
204. A.L. Cheng, C.H. Hsu, and J.K. Lin Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions Anticancer Res 21 2001 2895 2900
205. B. Rai, J. Kaur, and R. Jacobs Possible action mechanism for curcumin in pre-cancerous lesions based on serum and salivary markers of oxidative stress J Oral Sci 52 2010 251 256
206. K.M. Pisters, R.A. Newman, and B. Coldman Phase I trial of oral green tea extract in adult patients with solid tumors J Clin Oncol 19 2001 1830 1838
207. J.L. Schwartz, V. Baker, and E. Larios Molecular and cellular effects of green tea on oral cells of smokers: a pilot study Mol Nutr Food Res 49 2005 43 51
208. F.R. Khuri, J.J. Lee, and S.M. Lippman Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients J Natl Cancer Inst 98 2006 441 450